D95. CHALLENGES AND ADVANCES IN COVID-19

A Selective Leukotriene B4 Antagonist, Acebilustat, for Treatment of Outpatients With COVID-19 Disease: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6573 J. Levitt, H. Hedlin, S. Duong, D. Lu, J. Lee, N. Elkarra, B. Pinsky, E. Heffernan, E. Springman, H. Bonilla, J. Parsonnet, R. Zamanian, J. Langguth, J. Bollyky, C. Khosla, M. Nicolls, M. Desai, R. Moss, A. Rogers

Evidence of Post-infection Vaccination Correlation With the Severity of Opacities and Consolidations on the Lung Parenchyma of Post-acute SARS-CoV-2 Patients

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6579 D. Carmo, R. A. Tudas, A. Comellas, A. Pezzulo, R. Villacreses, J.L. Cho, J. Zabner, L. Rittner, R.A. Lotufo, J. Reinhardt, S. Gerard

Cova Results From a Double-blind, Placebo-controlled Phase 2/3 Study to Assess Efficacy and Safety of BIO101 in Hospitalized Severe COVID-19 Patients

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6576 G. B. Nair, W. Dioh, M. Chabane, C. Tourette, S. Rabut, M. Louze, L. E. Esmeraldino, S. Camelo, J. Mariani, M. Latil, R. Lafont, P. Dilda, S. Agus, R. Maanen, S. Veillet, C. Morélot-Panzini, G. Plantefeve, S. Lobo